Jump to content

Tia Turner

Tia TurnerEducation:

Hofstra University, B.S. (2013)
Hometown: Hewlett, New York
PhD Advisor: J. Chuck Harrell, PhD
Graduate Program: CTS/CMM (Pathology)

 

Research Interests:

Tia’s research interests lie primarily in the fields of oncology and neuroscience. Before joining the MD/PhD Program, she spent a year and a half working in a brain tumor lab, where she studied the influence of microglia on the progression and treatment of glioblastoma multiforme in an effort to discover novel therapeutic strategies for this malignancy. She is intrigued by the cellular and molecular mechanisms underlying tumor progression, invasion and metastasis, and therapeutic resistance, as well as the involvement of the immune system in cancer, with a particular focus on the development and preclinical testing of novel drugs that interfere with the malignant behavior of tumor cells and/or enhance the sensitivity of tumor cells to radiation therapy and chemotherapeutic agents. She is also interested in the study of neurological emergencies such as stroke and traumatic brain injury.

Personal Bio:

Tia grew up in Hewlett, New York, on the southwest shore of Long Island. She graduated in May 2013 with a Bachelor of Science from Hofstra University. Although she lived and attended college on Long Island, she frequently visited New York City on the weekends with family and friends. In addition to academics and research, Tia is passionate about music – she loves to sing and play piano, violin, and guitar. She also enjoys attending concerts and live theater, indulging in international cuisine, imbibing copious amounts of good coffee, and being outdoors. She loves Richmond because of its great balance of city life and suburban life, its convenient accessibility to diverse areas and activities, its friendly population, and its milder winters.

Publications:

Miller IS, Didier S, Murray DW, Turner TH, Issaivanan M, Ruggieri M, Al-Abed Y, and Symons M. Semapimod sensitizes glioblastoma tumors to ionizing radiation by targeting microglia. PLoS One. 2014;9(5):e95885. doi: 10.1371/journal.pone.0095885.